Down 60%: Is OncoGenex a Bad News Buy?

Shares of OncoGenex Pharmaceuticals (NASDAQ: OGXI) were crushed today, after the company's most advanced drug candidate, Custirsen, flopped in a phase 3 trial.

The drug did not improve median overall survival, the primary endpoint of its late-stage trial in patients with metastatic castration-resistant prostate cancer (or CRPC), in a statistically significant way. When taken in combination with prednisone and docetaxel, Custirsen helped generate median overall survival of 23.4 months, as compared to 22.2 months for patients taking prednisone and docetaxel only.

OncoGenex has Custirsen in late-stage trials for several other indications and another drug candidate, Apatorsen, in mid-stage trials (some of which are due to read out later this year). So, should investors consider the massive drop an opportunity to get shares at a cheaper price? In the video below, Motley Fool health care analysts David Williamson and Michael Douglass answer.

Even if OncoGenex bounces back from today's mauling, it could have serious trouble keeping up with this top stock
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2933853, ~/Articles/ArticleHandler.aspx, 8/31/2015 3:59:39 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated Moments ago Sponsored by:
DOW 16,550.04 -92.97 -0.56%
S&P 500 1,975.32 -13.55 -0.68%
NASD 4,780.43 -47.90 -0.99%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 3:43 PM
OGXI $2.90 Up +0.22 +8.21%
OncoGenex Pharmace… CAPS Rating: **
TEVA $64.47 Down -0.56 -0.86%
Teva Pharmaceutica… CAPS Rating: ****